國藥現代(600420.SH):子公司的注射用頭孢曲松鈉(2g)獲批在德國上市
格隆匯7月19日丨國藥現代(600420.SH)公吿,近日,公司控股子公司國藥集團致君(深圳)製藥有限公司在德國設立的全資子公司DALI Pharma GmbH(簡稱“DALI Pharma”)收到德國聯邦藥品和醫療器械機構(BfArM)核准簽發的注射用頭孢曲松鈉(2g)的上市許可。
該藥的適應症為頭孢曲松鈉為長效、廣譜的第三代頭孢菌素類抗生素,臨牀上一般用於治療敏感菌所致的細菌性腦膜炎、社區和醫院獲得性肺炎、腹部感染、併發性尿道感染(包括腎盂腎炎)、骨和關節感染、皮膚和軟組織感染、梅毒以及細菌性心內膜炎等。
本次DALIPharma的注射用頭孢曲松鈉(2g)獲得德國上市許可,標誌着DALIPharma具備了在歐盟市場銷售該產品的資格,將對公司拓展歐盟市場帶來積極影響,公司後續將積極推進該產品在歐盟市場上市銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.